Active, not recruitingPhase 1NCT04616248

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Studying Bone sarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Southern California
Principal Investigator
Fumito Ito, MD
University of Southern California
Intervention
Anti-CD40 Agonist Monoclonal Antibody CDX-1140(biological)
Enrollment
14 enrolled
Eligibility
18 years · All sexes
Timeline
20232028

Study locations (2)

Collaborators

National Institutes of Health (NIH)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04616248 on ClinicalTrials.gov

Other trials for Bone sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Bone sarcoma

← Back to all trials